Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Briakinumab> ?p ?o. }
Showing items 1 to 56 of
56
with 100 items per page.
- Briakinumab abstract "Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.Like ustekinumab, the antibody targets the interleukins 12 and 23.".
- Briakinumab atcPrefix "L04".
- Briakinumab atcSuffix "AC09".
- Briakinumab casNumber "339308-60-0".
- Briakinumab fdaUniiCode "978I8M0P8X".
- Briakinumab wikiPageID "25230853".
- Briakinumab wikiPageRevisionID "604459849".
- Briakinumab atcPrefix "L04".
- Briakinumab atcSuffix "AC09".
- Briakinumab bioavailability "N/A".
- Briakinumab c "6376".
- Briakinumab casNumber "339308".
- Briakinumab chemspiderid "NA".
- Briakinumab h "9874".
- Briakinumab hasPhotoCollection Briakinumab.
- Briakinumab legalStatus "investigational".
- Briakinumab mabType "mab".
- Briakinumab molecularWeight "146.5".
- Briakinumab n "1722".
- Briakinumab o "1992".
- Briakinumab s "44".
- Briakinumab source "u".
- Briakinumab target "IL-12 and IL-23".
- Briakinumab type "mab".
- Briakinumab unii "978".
- Briakinumab verifiedfields "changed".
- Briakinumab verifiedrevid "459982272".
- Briakinumab watchedfields "changed".
- Briakinumab subject Category:Experimental_medical_treatments.
- Briakinumab subject Category:Immunosuppressants.
- Briakinumab type Abstraction100002137.
- Briakinumab type Act100030358.
- Briakinumab type Activity100407535.
- Briakinumab type Care100654885.
- Briakinumab type Event100029378.
- Briakinumab type ExperimentalMedicalTreatments.
- Briakinumab type PsychologicalFeature100023100.
- Briakinumab type Treatment100658082.
- Briakinumab type Work100575741.
- Briakinumab type YagoPermanentlyLocatedEntity.
- Briakinumab type Drug.
- Briakinumab type DrugProduct.
- Briakinumab type FunctionalSubstance.
- Briakinumab comment "Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.Like ustekinumab, the antibody targets the interleukins 12 and 23.".
- Briakinumab label "Briakinumab".
- Briakinumab label "Briakinumab".
- Briakinumab label "Briakinumab".
- Briakinumab label "برياكينوماب".
- Briakinumab sameAs Briakinumab.
- Briakinumab sameAs Briakinumab.
- Briakinumab sameAs m.09ghjv4.
- Briakinumab sameAs Q3644426.
- Briakinumab sameAs Q3644426.
- Briakinumab sameAs Briakinumab.
- Briakinumab wasDerivedFrom Briakinumab?oldid=604459849.
- Briakinumab isPrimaryTopicOf Briakinumab.